sb 206553 has been researched along with Adverse Drug Event in 1 studies
SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hajjo, R | 1 |
| Grulke, CM | 1 |
| Golbraikh, A | 1 |
| Setola, V | 1 |
| Huang, XP | 1 |
| Roth, BL | 1 |
| Tropsha, A | 1 |
1 other study available for sb 206553 and Adverse Drug Event
| Article | Year |
|---|---|
Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Topics: Algorithms; Binding, Competitive; Databases, Factual; Dexfenfluramine; Drug-Related Side Effects and | 2010 |